Inotuzumab ozogamicin as novel therapy in lymphomas

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Dagher R, Cohen M, Williams G, Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008;44:2350-6
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008;19:99-113
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-73
   PubMed Web of Science ®Google Scholar
• Wong BY, Gregory SA, Dang NH. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest 2007;25:495-501
   PubMed Web of Science ®Google Scholar
• Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005;88:1-50
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Partida-Sanchez S, Donis-Hernandez R, Expression and function of CD22, a B-cell restricted molecule. Scand J Immunol 2002;55:343-51
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34
   PubMed Web of Science ®Google Scholar
• Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 1995;154:4466-75
   PubMed Web of Science ®Google Scholar
• Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998;10:287-97
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas J, Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, Phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-23
   PubMed Web of Science ®Google Scholar
• Linden O, Hindorf C, Cavallin-Stahl E, Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11(14):5215-22
   PubMed Web of Science ®Google Scholar
• Boghaert ER, Khandke KM, Sridharan L, Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 µl) blood samples. Cancer Chemother Pharmacol 2008;61:1027-35
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Popplewell A, Tickle S, Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 2005;54:11-24
   PubMed Web of Science ®Google Scholar
• Advani A, Gine E, Gisselbrecht C, Preliminary report of a Phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts [abstract 230]. Blood 2005;106:70a
   Web of Science ®Google Scholar
• Tobinai K, Ogura M, Hatake K, Phase I and pharmacokinetic study of inotuzumab ozogamicin (CMC-544) as a single agent in Japanese patients with follicular lymphoma pretreated with rituximab. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 1565
   Google Scholar
• Advani A, Coiffier B, Czuczman MS, Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a Phase I study. J Clin Oncol 2010;28(12):2085-93
   PubMed Web of Science ®Google Scholar
• Fayad L, Patel H, Verhoef G, Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a Phase 1/2 study. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 266
   Google Scholar
• Johnson P, Fayad L, Coiffier B, Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in recurrent/refractory follicular lymphoma or diffuse large B-cell lymphoma European Hematology Association Annual Meeting Abstracts [abstract 0407]. Haematologica 2009;94:165
   Web of Science ®Google Scholar
• DiJoseph JF, Armellino DC, Khandke K, CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-Hodgkin's lymphoma:[abstract 500]. Eur J Cancer 2002;38(Suppl 7):S150
   Google Scholar
• DiJoseph JF, Armellino DC, Boghaert ER, Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004;103:1807-14
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Goad ME, Dougher MM, Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9
   PubMed Web of Science ®Google Scholar
• Fayad L, Patel H, Verhoef G, Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a Phase 1 study. ASH Annual Meeting Abstracts [abstract 2711]. Blood 2006;108:766a
   Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Kalyandrug L, Damle NK. Anti-tumor activity of CMC-544 in combination with rituximab [abstract 700]. Proc Am Assoc Cancer Res 2005;46:165
   Google Scholar
• DiJoseph JF, Dougher MM, Kalyandrug LB, Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242-9
   PubMed Web of Science ®Google Scholar
• Takeshita A, Yamakage N, Shinjo K, CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 2009;23:1329-36
   PubMed Web of Science ®Google Scholar
• Dang NH, Smith MR, Offner F, Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544)+ rituximab: clinical activity including survival in patients with recurrent/refractory follicular or ‘aggressive’ lymphoma. ASH Annual Meeting Abstracts [abstract 584]. Blood 2009;114:242
   Web of Science ®Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240-5
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Yamakage N, CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009;146(1):34-43
   PubMed Web of Science ®Google Scholar